bluebird bio (BLUE) Stock Price, News & Analysis

Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Key Stats

• Today's Range: $7.94 to $9.80
• 50-Day Range: $5.89 to $14.73
• 52-Week Range: $5.80 to $38.40
• Volume: 899,239 shs
• Average Volume: 398,183 shs
• Market Capitalization: $82.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.14
• Consensus Rating: Hold

bluebird bio Stock Analysis - MarketRank™

bluebird bio scored higher than 50% of companies evaluated by MarketBeat, and ranked 561st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

bluebird bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 6 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

bluebird bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for bluebird bio are expected to grow in the coming year, from ($1.35) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of bluebird bio is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of bluebird bio is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

bluebird bio has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

509.87% of the outstanding shares of bluebird bio have been sold short.

Short Interest Ratio / Days to Cover

bluebird bio has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in bluebird bio has recently increased by 13.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

bluebird bio does not currently pay a dividend.

Dividend Growth

bluebird bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

509.87% of the outstanding shares of bluebird bio have been sold short.

Short Interest Ratio / Days to Cover

bluebird bio has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in bluebird bio has recently increased by 13.59%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.10

News Sentiment

bluebird bio has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for bluebird bio this week, compared to 5 articles on an average week.

Search Interest

24 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $403.00 in company stock.

Percentage Held by Insiders

Only 1.40% of the stock of bluebird bio is held by insiders.

Percentage Held by Institutions

87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BLUE Stock Analysis - Frequently Asked Questions

How have BLUE shares performed this year?

bluebird bio's stock was trading at $27.60 on January 1st, 2024. Since then, BLUE shares have decreased by 69.2% and is now trading at $8.50.
View the best growth stocks for 2024 here.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings data on Friday, September, 27th. The biotechnology company reported ($8.40) earnings per share for the quarter, missing the consensus estimate of ($8.00) by $0.40. The biotechnology company had revenue of $16.10 million for the quarter, compared to analyst estimates of $16.09 million. bluebird bio had a negative trailing twelve-month return on equity of 322.46% and a negative net margin of 565.74%.

When did bluebird bio's stock split?

bluebird bio's stock reverse split on the morning of Friday, December 13th 2024. The 1-20 reverse split was announced on Wednesday, December 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are bluebird bio's major shareholders?

bluebird bio's top institutional investors include Geode Capital Management LLC (2.42%), State Street Corp (1.98%), FMR LLC (1.28%) and BNP Paribas Financial Markets (0.19%). Insiders that own company stock include Andrew Obenshain, Nick Leschly, Jason Cole, Thomas J Klima, Richard A Colvin, Christopher Krawtschuk, Anne-Virginie Eggimann and Jessica Whitten.
View institutional ownership trends.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that bluebird bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 9/27/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BLUE
• CUSIP: N/A
• CIK: 1293971
• Web: www.bluebirdbio.com
• Phone: (339) 499-9300
• Fax: N/A
• Employees: 323
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $49.14
• High Stock Price Target: $120.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +478.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($37.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-211,910,000.00
• Net Margins: -565.74%
• Pretax Margin: -551.41%
• Return on Equity: -322.46%
• Return on Assets: -53.17%

Debt

• Debt-to-Equity Ratio: 0.37
• Current Ratio: 0.51
• Quick Ratio: 0.33

Sales & Book Value

• Annual Sales: $53.12 million
• Price / Sales: 1.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.78 per share
• Price / Book: 4.78

Miscellaneous

• Outstanding Shares: 9,722,000
• Free Float: 191,722,000
• Market Cap: $82.64 million
• Optionable: Optionable
• Beta: 0.72